Ranbaxy Can't Shake MDL Antitrust Claims As Trial Nears
Ranbaxy Pharmaceuticals Inc. didn't need to ever sell a dose of a drug to have wielded monopoly power over it, a Boston federal judge ruled Monday, rejecting the company's bid for...To view the full article, register now.
Already a subscriber? Click here to view full article